Sequencing Follow-up; Sequencing, Prenatal;
Expected Turnaround Time
14 - 28 days
Turnaround time is defined as the usual number of days from the date of pickup of a specimen for testing to when the result is released to the ordering provider. In some cases, additional time should be allowed for additional confirmatory or additional reflex tests. Testing schedules may vary.
Amniotic fluid, direct and cultured cells, or chorionic villus (CVS) direct and cultured cells
15 mg CVS, one T-25 confluent flask of fetal cells or 10 mL amniotic fluid
Amniotic fluid: Orange-top polypropylene tube CVS: Laboratory-provided screw-top tubes with sterile transport medium
Prenatal: Call a laboratory genetic coordinator prior to obtaining any specimens. All prenatal specimens (including cord blood) must be accompanied by a maternal blood specimen for analysis of possible maternal cell contamination.
Amniotic fluid: Discard first 2 mL, then collect 10 mL in 15-mL orange-top polypropylene tube. Additional specimen must be obtained for back-up culture at a LabCorp cytogenetics laboratory or another facility.
Maintain specimen at room temperature or refrigerate.
This test is available for partner testing when a carrier is identified through universal carrier screening (Inheritest Carrier Screen NGS - Comprehensive Panel (142 genes)  or Inheritest Carrier Screen NGS - Ashkenazi Jewish Panel (39 Genes)  or Inheritest Carrier Screen NGS - Society Guided Panel (12 Genes)  or Inheritest Gene-specific Sequencing, NGS ).
This interpretation is based on the clinical information provided and the current understanding of the molecular genetics of the disease(s) tested. This analysis does not rule out the presence of disease-causing mutations in other regions of the gene(s) analyzed or in other genes, and it does not rule out the presence of large deletion or duplication mutations or complex rearrangements. False-positive or negative results may occur for reasons that include genetic variants, technical handling, blood transfusions, bone marrow transplantation, mislabeling of samples, erroneous representation of family relationships, or contamination of a fetal sample with maternal cells.
This test was developed, and its performance characteristics determined, by LabCorp. It has not been cleared or approved by the US Food and Drug Administration (FDA). The FDA has determined that such clearance or approval is not necessary.
DNA is isolated and specific gene regions amplified by the polymerse chain reaction (PCR). Targeted mutations are detected by direct DNA sequencing using capillary gel electrophoresis and fluorescence detection.